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Summary.-The experiments aimed at evaluating the optimal parameters in the
chemo-immunotherapeutic treatment of the L1210 lymphoid leukaemia grafted to
[female BALB/c (H2d) x male DBA/2 (H2d)]Fl hybrid mice, hereafter referred to as
CDF1 mice.
Invitro irradiation of leukaemic ascitescells byX- or y-rays and subsequent inocula-
tion in mice showed that optimum immunogenicity is radiation dose-dependent.
Grafting mice with l07 leukaemic ascites cells irradiated at optimum dose (80 GyX-
or y-rays) delays mortality of the animals when challengedlaterwith untreated L1210
cells, but is unable to cure mice. By contrast, specific immunoprophylaxis induced by
Micrococcus, complement-triggering polysaccharides or BCG and irradiated leu-
kaemic cells was able to protect mice against grafts of 104 L1210 cells. The i.p. route
was notably superior to the i.v. route.
When mice bearing advanced L1210 tumour were treated by chemotherapy (12 mg/
kg of BCNU) on Day 6 5 after grafting 104 L1210 cells and subsequently treated by
immunotherapy, a very high percentage (up to90o%) of mice with 108 leukaemic cells
could be cured by repeated 1mg injections of bacterium or polysaccharide, and
challenge with irradiated leukaemic cells was unnecessary.
Because of the high cure rate obtained, the very regular response pattern and the
non-pathogenicity, the bacterium Micrococcus Iysodeikticus would seem a promising
new candidate for chemo-immunotherapeutic antitumour strategies.
THE BCG STRAIN of Mycobacterium
bovis has become a popular agent for
immunotherapy of cancer. However, the
general use of BCG is made difficult be-
cause of many disadvantages: BCG can
cause ulceration, pyrexia, abnormal liver
function, tuberculosis and, in a few repor-
ted cases, death or even enhancement of
tumour growth (Hunt et al., 1973; Spark
et al., 1973; Mansell & Krementz, 1973).
Micrococcus lysodeikticus is a non-
pathogenic and easy-to-eliminate (sub-
strate of lysozyme) Gram-positive bac-
terium, that elicits the production of large
amounts ofantibodies ofrestricted hetero-
geneity and clonal dominance in rabbits
(Van Hoegaerden et al., 1975) and mice
(Verloes et al., 1977a; b). Since antimicro-
coccus antibodies are directed against
carbohydrates (Wikler, 1975) and bind to
certain lymphocytes (Verloes & Kanarek,
1976; De Baetselier et al., 1977) and to
severaltumour-cell types (L1210 lymphoid
cells, Ehrlich carcinoma cells) (Verloes
et al., 1976) but not to erythrocytes
(Verloes et al., 1979a), they are believed to
act on cells in a similar way to the lectins
but with greater discrimination and less
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toxicity for normal cells (Verloes et al.,
1976). The interaction of antimicrococcus
antibodies with receptors on neoplastic
cells was confirmed by others, and a cell-
cycle-stage dependency was established
(Grooten & Hamers, 1979).
Although a single injection of Micro-
coccus suspended in incomplete Freund
adjuvant does not display an adjuvant
effect for protein antigens (Kotani et al.,
1975), we have demonstrated that multiple
Micrococcus injections, like live BCG
injections, elicit a comparable number of
plaque-forming cells to sheep erythrocytes,
whereas Micrococcus-treated mice showed
markedly less toxicity than BCG-treated
animals (Verloes et al., 1979b). We have
also previously demonstrated that Micro-
coccus lysodeikticus is able to activate
complement by the alternative pathway
(Verloes et al., 1977b) and the importance
of this phenomenon in inflammation is
well documented (Bianco et al., 1976;
Ward, 1967, Schorlemmer et al., 1976). In
an attempt to maximize the chemothera-
peutic response to antitumour agents by
immunotherapy, this study was under-
taken to compare therapeutic values of
Micrococcus with the activitygeneratedby
structurally related complement-triggering
polysaccharides and BCG. Immunological
monitoring after cytotoxic chemotherapy
is likely to be highly dependent on the
immune status of the host, and subse-
quently correlated with the drug used and
the chemotherapeutic regimen. Further-
more, since it was shown that chemo-
immunotherapy of L1210 leukaemia by a
drug (cyclophosphamide) and an antigen
(L1210 cells) depending on the protocol,
may be either non-significant (Mathe
et al., 1977) or effective (Kataoka et al.,
1978), special attention was paid to deter-
mine the experimental parameters that
yield an optimal antitumour response.
MATERIAL AND METHODS
Micrococcus lysodeikticus (ML), cell wall
of ML, cell-wall-conjugated chitin and chitin
were prepared as earlier described (Verloes et
al., 1976).
Bacillus Calmette-Guerin.-Vials contain-
ing 100 mg of lyophilized Bacillus Calmette-
Guerin (BCG-SP) for scarification were pur-
chased from the Pasteur Institute, Brussels.
After reconstitution with the appropriate
diluent and further dilution in Hanks'
balanced salt solution (HBSS) the suspension
was kept at 4°C and used within 2 weeks.
ZymosanA.-The cell wall ofSaccharomyces
cerevisiae (yeast) was commercially available
(Lot No. 34C-2650-Sigma Company). In-
soluble cell walls were boiled for 1 h in 0.9%
NaCl solution, washed x3 with PBS and
centrifuged at 3000 g for 20 min.
Inulin.-The f(2-1) polyfructoside inulin
(Lot No. 519 903) was obtained from J.T.
Baker Company.
Dextran sulphate (sodium salt).-The
material used was a(l-4) polysaccharide with
approximate mol. wt of 500,000, and was
purchased from Pharmacia Fine Chemicals
(Lot No. 7126).
BCNU.-Vials containing 100 mg of 1,3
bis-(2-chloroethyl)-1-nitrosourea, named BC-
NU (NSC-409962), were obtained from the
National Cancer Institute, Bethesda, Mary-
land, U.S.A. After reconstitution with the
appropriate diluent and further dilution in
ice-chilled HBSS, the solution was injected
within 2 h.
Animals.-Female [female BALB/c (H2d)
x male DBA/2 (H2d)] F1 hybrid mice (CDF1)
were purchased from Charles River Breeding
Laboratories, Calco, Italy. Those mice were
stored 3 weeks in an isolation room and used
before they were 10 weeks old. Animals
weighing 19-23 g were used.
Tumour. L1210 leukaemia was originally
induced in female DBA/2 mice with methyl-
cholanthrene in ether (Law et al., 1949). The
L1210 leukaemia, obtained from Dr A.
Bogden (Mason Research Institute, Worces-
ter, Mass., U.S.A.), was maintained in ascitic
form by weekly transfer in DBA/2 mice.
Animals were injected i.p. to obtain the
ascitic form of leukaemia, or i.v. to obtain
the blood form of leukaemia. Animals were
randomized into test and control groups.
Mean survival time (MST) of treated and
control mice as well as the doses and timing
of each experiment are specified in the tables
and figures. Mice still tumour-free on the 90th
day after tumour grafting were considered as
long-term survivors and eliminated from
evaluation of the mean survival time. No
relapses after Day 90 were seen.
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RESULTS
Effect of irradiation source and dose on
lethality and immunogenicity ofL1210 cells
L1210 cells grown as ascites in DBA/2
mice were aspirated from the mouse peri-
toneal cavity 7 days after grafting 104
cells i.p. These cells were diluted in HBSS
and irradiated at different doses (0, 40,
80, 120 and 170 Gy) by a y-ray-emitting
60Co Siemens apparatus at a dose rate of
3.55 Gy/min at 200 kV. 107 irradiated cells
were grafted i.p. to intact CDF1 mice
and the mortality was recorded. Whereas
mice challenged with unirradiated cells
died 6-50 days + 0 55 later, mice injected
with 4OGy-irradiated L1210 cells died
12-83 + 0 75 days after injection. No
mortality was seen with the other grafts.
When surviving mice were rechallenged 30
days later with 104viable leukaemic L1210
cells, we found a 92, 18 and 7% increase in
MST over control mice respectively for the
80, 120 and 17OGy schedules, as seen in
Table I. In order to compare the effect of
the irradiation source on lethality and
immunogenicity of L1210 cells, the same
experiment was performed using an Eura-
tom X-ray apparatus (250 kV, 12 mA,
0 95 Gy/min). Whereas 107 unirradiated
cells killed mice 5 50 days + 0-71 after
grafting, 4OGy-irradiated leukaemic cells
killed mice 14 90 days+ ± 91 after chal-
lenge. No mortality was seen with the
other grafts. When survivors were re-
challenged with 104 cells i.p., we found a
53, 48 and 27% increase in MST over
controls respectively, as seen in Table I.
Long-term survivors (>90 days) were
never recorded. This leads us to conclude
that the optimal irradiation dose (80 Gy)
may exist irrespective of irradiation
source.
Specific anti-LI210 immunoprophylaxis by
a combination of irradiated leukaemic
LI210 cells and bacterium orpolysaccharide
To evoke a specific immune response,
randomized intact CDF1 mice were immu-
nized by grafting 107 irradiated (80 Gy
y-rays) L1210 ascites cells simultaneously
with 1 mg of bacterium or polysaccharide
either i.p. or i.v. Two months later,
immunized mice received a transplant of
104 viable L1210 cells according to the
immunization route. As shown in Table
TABLE I.-Effect ofirradiation dose on lethality and immunogenicity of L1210 leukaemic
cells
Irradiation of
L1210 cells
Dose
Source (Gy)
X-rays 0
y-rays
40
80
120
170
0
40
80
120
170
MST (days)
±s.d.t after
grafting 107
irr. cells
5 50+ 0-71
14-90+ 1-91
6-50+ 0 55
12-83 + 0 75
MST (days)
+s.d.t
rechallenge
with 104 cells
10-54 + 0-66
(controls)
16-14+ 1-34*
15-60 + 3-89*
13-43 + 7-91
9 50+0-71
(controls)
18-25 + 15-5
11-25 + 1-26
10-16 + 0-41
% of
long-term
ILS§ survivors
(%) (Day 90)
0 0
53
48
27
0
92
18
7
0
0
0
0
0
0
0
Leukaemic L1210 cells grown as ascites in DBA/2 mice were irradiated at different doses and 107 cells
were grafted i.p. in CDF1 mice.
Surviving mice were rechallenged one month later with 104 L1210 cells and MST ofrechallenged mice was
compared to that of tumour-challenged control mice.
* Significant at P < 0-001 (Student-Fisher t test).
t For mice dying before 90 days after grafting cells.
t 10-20 mice in each experiment.
§ ILS=increase in lifespan of treated mice over control mice.R. VERLOES, G. ATASSI, P. DUMONT AND L. KANAREK
TABLE II.-Specific anti-L1210 immunoprophylaxis byprevaccination with irradiated cells
and micrococcus, BCG or related polysaccharides
Treatment
- Route
Irradiated (treatment+
cells Agent transplant)
+ BCG i.v.
+ Micrococcus i.v.
+ Zymosan i.v.
+ Chitin i.v.
+ Inulin i.v.
+ Dextran sulphate i.v.
+ (controls) i.v.
+ BCG i.p.
+ Micrococcus i.p.
+ Zymosan i.p.
+ Chitin i.p.
+ Inulin i.p.
+ Dextran sulphate i.p.
+ (controls) i.p.
- (controls) i.p.
% of
long-term
survivors
(Day 90)
0
12-5
0
0
14-0
14-0
0
86-0
71-0
86-0
0
57 0
14-0
17-0
0
MST (days)
+s.d.
12-00+ 2-31
11-14+0-69
10-43 + 0-53
12-50+ 4-23
8-67 + 3-72
10-83 + 0-98
14-14+ 5-81
10-00+ 0.0
11-00+ 0-0
11-00+ 0.0
10-33 + 0-52
12-33 + 2-52
12-33 + 3-01
11-20+0 45
10-22 +0 44
ILS*
(%)
17
9
2
22
0
6
38
0
8
8
1
21
21
10
0
t test
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
Intact CDF1 mice were immunized by grafting 107 irradiated (80 Gy, y-rays) in vivo-grown L1210 cells
and 1 mg of different agents, 2 months before transplantation of 104 leukaemic L1210 cells; 10-20 mice
per expt.
* ILS =increase in lifespan of treated (but tumour-bearing and dying before 90 days) mice over control
mice.
II, thei.p. route generated a moreeffective
immunoprotection. Our data also indicate
that immunoresponse leads to an all-or-
none reaction; it is able to induce long-
term survivors but unable to prolong
significantly mean survival of the other
immunized and tumour-bearing mice.
This fact does not weaken the results,
especially since the number of animals
surviving to Day 90 is very high. There
were slight differences in immunoprotec-
tion rates for zymosan (86%), Micrococcus
(71%) and BCG (86%). From these
experiments, we also learned that the i.p.
route definitely yielded better results, and
consequently was used in the following
chemo-immunotherapeutic trial.
Chemo-immunotherapy: drug design and
experimental control
These experiments were conducted to
maximize the chemotherapeutic response
ofanantitumourdrugtherapybyimmuno-
therapy. We concentrated our efforts on
advanced (terminal) disease for which
treatment is initiated several days before
the expected death day of controls. For
that purpose, CDF1 mice were given i.p.
104 L1210 cells on Day 0 and the tumour
was allowed to grow and spread. On Day
6-5, when the tumour burden is considered
to reach 108 cells (Cantrell et al., 1976)
and treatment by bacterial immuno-
adjuvant only (BCG or ML) proved to be
unsuccessful, mice received one single i.p.
injection of BCNU (12 mg/kg) and were
subsequently treated by immunotherapy
on Day 8, either by 107 irradiated (80 Gy
y-rays) in vivo-grown L1210cellscombined
with 1 mg ofbacterium or polysaccharide,
or by 1 mg ofbacterium or polysaccharide
alone. This experimental protocol for
chemotherapy was adopted from Cantrell
et al. (1976). All untreated control mice
died after 10-22 days + 0 44, whereas mice
treated by chemotherapy died after 19-80
days+ 4 34 and mice treated by chemo-
therapy and 107 irradiated cells died after
20-80 days+ 5-07. No long-term survivors
were recorded.
As seenin Table III, a single administra-
tion of bacteria or some complement-
triggering polysaccharides induces an ap-
preciable % of long-term survivors ( > 90
days) which are freed from 108 leukaemic
L1210 cells.
Looking at these data, we are tempted
to believe that the administration of
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TABLE III.-Effect of a single injection ofMicrococcus, BCG and related polysaccharides
inspecific or non-specific immunotherapy ofL1210 leukaemia after BCNU chemotherapy
Immunotherapy
Irradiated
cells Agents
+ BCG
+ Micrococcus
+ Zymosan
+ Chitin
+ Inulin
+ Dextran sulphate
+ Cell-wall chitin
+ Control (chemotherapy only)
_ BCG
- Micrococcus
- Zymosan
- Chitin
- Inulin
- Dextran sulphate
- Cell-wall chitin
- Control (chemotherapy only)
No immunotherapy and no
chemotherapy
+ No chemotherapy
% of
long-term
MST (days) survivors
+s.d. (Day 90)
26-71 + 10-36
27-89+ 5-11
30-20+ 16-39
28-00 + 14-68
24-29 + 9-81
16-33 + 2-55
22-60+ 4 70
20-80+ 5 07
26-43 + 8-94
22-90 + 5-34
28-00 + 9-54
29-13 + 7-26
24-29 + 5-12
19-83 + 7-17
22-80+ 9-68
19-80+ 4-34
25
10
50
20
30
10
0
0
12-5
0
50
11
30
14
0
0
10-22 + 0 44 0
10-20 + 0-42 0
Intact CDF1 mice received an i.p. transplant of 104 leukaemic L1210 cells on Day 0. They then received a
single i.p. injection of BCNU (12 mg/kg) on Day 6-5, followed by immunotherapy on Day 8 and an injection
of 107 irradiated (80 Gy y-rays) in vivo-grown L1210 cells combined with 1 mg bacterium or polysaccharide
alone; 10-20 mice per expt.
The increase in mean lifespan of mice treated by chemo-immunotherapy over mice treated by chemo-
therapy is expressed as a percentage.
irradiated ascites cells yields better results.
Using the same chemo-immunotherapeutic
protocol, we have investigated next
whether repeated administration of com-
plement triggers or bacteria on Days 9, 10,
11, and 12 or on Days 11, 14, 17 and 20
might increase the number of long-term
survivors (mice cured on Day 90). By
combining chemotherapy with nonspecific
(no irradiated cells) immunotherapy, we
are able, except for chitin, to cure 30-
90% of mice with 108 leukaemic cells by
1mg injections on Days 8, 9, 10, 11 and 12,
and 40-90% of mice by injections on
Days 8, 11, 14, 17 and 20. In both treat-
ment schedules, the administration of
Micrococcus yielded the highest scores of
long-term survivors (90%), as illustrated
in Figs 1 and 2.
In a final set of experiments, we have
investigated whether inoculation of 107
leukaemic cells irradiated at optimal dose
(80 Gy y-rays) could improve the chemo-
immunotherapeutic schedule described
above. As illustrated in Figs 3 and 4, we
were able to induce long-term survivors
by this combination ofchemotherapy with
immunotherapy in 30-90% ofthe animals
injected on Days 8, 9, 10, 11 and 12 and in
30-90% of those injected on Days 8, 11,
14, 17 and 20. By contrast, mice treated by
chemotherapy only died after 26-12 days
+ 9-72, yielding 13% of long-term sur-
vivors (2/15), whereas mice treated by
chemotherapy and 107 irradiated cells
survived 25-67 days + 5-26 with also 13%
of long-term survivors (2/15) (the latter
data do not appear in Figs 1-4).
We conclusively demonstrated that
Micrococcus, zymosan A andinulin applied
after BCNU therapy yielded an appre-
ciably greater percentage (P < 0.005) of
cured mice than leukaemic mice given
BCNU chemotherapy only. The efficiency
of BCG chemo-immunotherapy critically
depended on the immunotherapeutic pro-
tocol. By contrast, chemo-immunotherapy
performed with cell-wall chitin, dextran
sulphate or chitin was less effective or
ineffective.
ILS
(%)
35
41
52
41
23
0
14
5
33
16
41
47
23
0
15
0
t test
NS
P<0-001
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
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FiGs 1-4. Effect of repeated administration of Microccus BCG and related polysaccharides in non-
specific chemo-immunotherapy of L1210 leukaemia. Intact CDF1 mice received an i.p. transplant
of 104 leukaemic L1210 cells on Day 0. They were then treated by a single i.p. injection of BCNU
(12 mg/kg) on Day 6-5, and treated by immunotherapy as an i.p. injection of 1 mg on Days 8, 9, 10,
11 and 12 (Fig. 1) or on Days 8, 11, 14, 17 and 20 (Fig. 2). Other mice were treated by
immunotherapy on Day 8 and received an i.p. injection of 107 irradiated (80 Gy y-rays) in
vivo-grown L1210 cells combined with 1 mg bacterium or polysaceharide. Treatment was
continued by i.p. lmg injections on Days 9, 10, 11 and 12 (Fig. 3) or on Days 11, 14, 17 and 20
(Fig. 4). Statistical evaluations were determined by x2 distribution for difference from mice given
BCNU only. NS =not significant.
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DISCUSSION
Many antigenic tumours such as L1210
leukaemia are poorly immunogenic (Can-
trell et al., 1976) and require stimuli to
elicitimmune responses (Glynnetal., 1963).
As more effective stimuli, we have used
BCG, Micrococcus and structurally related
complement-triggering polysaccharides.
Previous studies indicated that pretreat-
ment of mice with those agents alone was
insufficient to provide immunoprotection
against tumour grafting (Verloes et al.,
1978). We have therefore compared the
effect of different doses of X- or y-rays on
lethality of in vivo-grown (ascites) L1210
cells and their capability of inducing
a.
I.....
I.
1
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immunoprotectioni. Our results clearly
demonstrate an optimal irradiation dose
(80 Gy); the mortality of mice challenged
with radiated cells was delayed but no
cures were recorded. However, specific
antitumour immunoprophylaxis induced
by preimmunization with irradiated leu-
kaemic cells and bacteria orpolysaccharide
was more effective when we used the i.p.
than the i.v. route, and yielded a high
percentage of mice cured on the 90th day
after tumour grafting. Since it was shown
that L1210 leukaemia growth is accom-
panied by tumour-mediated immunosup-
pression (Huget et al., 1977), it would be
interesting to investigate whether the
kinetics of immunosuppression affects
similarly i.v. or i.p. challenged mice.
Although chloro-ethyl-nitrosoureas con-
stitute an established class of important
antitumour agents, repeated administra-
tion ofBCNU to human patients may pro-
duce a dramatic marrow toxicity (Schein
et al., 1978). Therefore, applying successful
immunotherapy after effective chemo-
therapy instead of maintenance chemo-
therapy, is one possibility for counteract-
ing long-lasting drug toxicity in humans
and mice, and reducing the probability of
in vivo selection of drug-resistant neo-
plastic cell clones, thus offering a chance of
cure. When tumour-bearing mice were
treated (once) by BCNU chemotherapy
6-5 days after inoculation of 104 leukaemic
cells and treated (once) on Day 8 by
immunotherapy, a considerable percentage
of long-term survivors was recorded. Our
best results were obtained with zymosan
(5000 survivors). However, administration
of Micrococcus yielded a very low per-
centage of suirviving mice (10%). This
might be due to the easy destruction and
elimination of the complement-triggering
bacterium Micrococcus (Verloes et al.,
1977b) by the polymorphonuclear leuco-
cytes and the subsequent exocytosis of
lysosomal enzymes (i.e. lysozyme) by these
cells (Schorlemmer et al., 1976). Probably
this also accounts for the observation that
repeated lmg Micrococcus injections en-
hance 5-fold the number of direct plaque-
forming cells to sheep erythrocytes, where-
as one injection displays no effect (Verloes
et al., 1979b). By using low doses ofBCNU
with nonspecific (without irradiated cells)
immunotherapy, we were able to cure up
to 9000 ofmice bearing 108 leukaemic cells
by repeated lmg injections of bacteria or
polysaccharides. Highest survival scores
were obtained with Micrococcus lysodeik-
ticus. Furthermore, although the data
presented do not demonstrate clearly the
superiority ofMicrococcus overzymosan or
inulin chemo-immunotherapy, we must
mention that antimicrococcus antibodies
selectively recognize epitopes on tumour
cells such as L1210 cells (Verloes et al.,
1976) and that repeated 1mg injections
of BCG( to intact mice produced a con-
siderable loss of weight which did not
occur after Micrococcus lysodeikticus (Ver-
loes et al., 1979b). The fact that the thera-
peutic values ofMicrococcus and zymosan
A were rather schedule-independent,
whereas values obtained with BCG were
critically influenced by timing and antigen
presentation, strengthens the interest in
Micrococcus. It is also obvious that re-
peated imnmunological treatments are more
effective than a single administration, and
that rechallenge with irradiated leukaemic
cells is not strictly required for this work-
ing schedule. Very probably, effective
cytotoxic chemotherapy provided immu-
nocompetent cells with immunogenic
material, and the immune system was
subsequently triggered by complement-
activating polysaccharides or bacteria. In
this perspective, it is worth mentioning
that a similar prevailing condition can
be created by intratumour cytotoxic
chemotherapy (followed by intra-
tumour immunotherapy) of inoperable
cancers where it is impossible to obtain
antigens.
The high cure rates obtained, the regu-
lar therapeutic response (at least asgood or
better than with BCG and zymosan) the
absence oftoxicity and the non-pathogen-
icity of Micrococcus lysodeikticus promote
this easy-to-eliminate bacterium (sub-
strate oflysozyme) as an attractive candi-
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date for new chemo-immunotherapeutic
antitumour strategies.
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